grant

Validation of Endopep-MS for qualitative detection of BoNT/A, /C, /CD, /D, and /DC in animal specimens and feed.

Organization UNIVERSITY OF CALIFORNIA AT DAVISLocation DAVIS, UNITED STATESPosted 1 Sept 2024Deadline 31 Aug 2026
FDANIHUS FederalResearch GrantFY2025
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY/ABSTRACT
Botulism is a serious paralytic disease that affects both humans and animals which is caused by botulinum

toxins (BoNTs). Animal botulism outbreaks in farm animals, in particular, not only affects animals but also

result in financial losses for the industry and increases the risk of human exposure to BoNTs through animal

products such as milk. To prepare for a response to the future outbreaks, a fast, sensitive, and reliable

detection method for BoNTs is needed. The Endopep-MS method is one of the most promising methods that

has been used for confirmation of human botulism by the Centers for Disease Control and Prevention (CDC)

for years. However, a comprehensive validation study of the Endopep-MS for animal specimens and feed is

lacking, and none of the veterinary diagnostic laboratories in the US have standard procedures for performing

this method. To fill the knowleage gap, our team at the California Animal Health and Food Safety Laboratory

(CAHFS), a founding member of VET-LIRN, is proposing a comprehensive validation study of the Endopep-MS

for qualitative detection of BoNT/A, /C, /CD, /D, and /DC in animal specimens and feed. Our study has three

specific aims as follows.

Specific Aim #1: To validate the Endopep-MS for qualitative detection of BoNT/A, /C, /CD, /D, and /DC

in animal specimens and feed. We will validate and compare the developed method to the standard mouse

bioassay (MBA) using toxin-spiked samples and archived samples collected during natural botulism cases.

The sample matrices include but are not limited to animal sera, liver, gastrointestinal contents, and feed.

Specific Aim #2: To develop monoclonal antibodies for the toxin extraction step in the Endopep-MS

method. Monoclonal antibodies are key for the Endopep-MS to achieve selectivity toward BoNT serotypes in

samples. Since there is currently only one source of the monoclonal antibodies in the US, we will collaborate

with Dr. Christina Tam at United States Department of Agriculture (USDA) and develop new monoclonal

antibodies for the method.

Specific Aim #3: To assess the effectiveness of polyclonal antibodies for the toxin extraction step in

the Endopep-MS method. The limited source of monoclonal antibodies can delay research development and

adoption of this method, an issue we have experienced ourselves. Alternately, polyclonal antibodies are

commercially available but the ability of polyclonal antibodies for BoNTs extraction has not been completely

explored. We will complete this knowledge gap by investigating capability of polyclonal antibodies for

extraction of BoNT/C, /CD, /D, and /DC.

If this project is funded and achieved, the lethal and time-consuming MBA that has been performed at CAHFS

for close to 30 years can be avoided. Our laboratory, as part of the Vet-LIRN, will have the Endopep-MS ready

to support botulism testing during outbreaks and large-scale animal feed emergency events.

Grant Number: 5U18FD008342-02
NIH Institute/Center: FDA

Principal Investigator: Karyn Bischoff

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →